Search Results

An in-depth commercial analysis of the UK-India Comprehensive Economic and Trade Agreement (CETA), exploring its transformative impact on bilateral pharmaceutical manufacturing, active pharmaceutical ingredient (API) supply chains, and consumer medicine pricing.

As the Turnberry Deal’s 15% tariff baseline takes hold, Brussels has formally requested carve-outs for €150 billion worth of European goods. The stakes are exceptionally high for Ireland’s €13B medical technology industry, where critical components face severe transatlantic margin pressures.

Jefferies has revised its debut-quarter US sales estimate for Eli Lilly's oral GLP-1 drug Foundayo (orforglipron) down to $71 million - well below the Wall Street consensus of $130 million and sharply below its own prior estimate of $85 million. With weekly prescriptions hovering around 20,000 and Novo Nordisk's oral Wegovy outpacing it on trajectory, the first oral non-peptide GLP-1 for obesity is generating a very different story than the hype suggested.

The UK government and the pharmaceutical industry have launched a series of pilot schemes designed to accelerate NHS patient access to innovative medicines - a direct consequence of the US-UK pharmaceutical trade arrangement that has already rewritten the terms of how Britain prices, approves, and funds new drugs. But with a BMJ analysis warning of £45 billion in diverted NHS resources and up to 229,000 excess deaths by 2036, the pilots are arriving in the middle of one of the most contested healthcare policy disputes in a generation.

Global research pipelines and venture capital inflows are concentrating in targeted cancer therapy with ADCs and next-generation cardiometabolic GLP-1 oral weight-loss compounds.

Northern Ireland-based Galen has received an expanded UK license for its emergency pain relief inhaler, Penthrox (methoxyflurane). The self-administered "green whistle" is now officially approved for use in conscious children aged six and older suffering from trauma-associated pain.

Moroccan pharmaceutical group Laprophan finalizes its acquisition of a controlling stake in Swiss pharmaceutical firm Rivopharm, securing a strategic industrial base in Europe and expanding its global footprint.

Enterprise Ireland has announced record total exports of €38.86 billion. With the Advanced Manufacturing and Life Sciences sector surging by 14% to €13.16 billion, we analyse what this means for Ireland's homegrown pharma ecosystem.

The Health Service Executive (HSE) is facing intense budgetary pressure as clinical demand for GLP-1 obesity medications skyrockets. We break down the restrictive funding, the "dreadful dichotomy" of access, and the surge in illegal online sales.

Discover the top 5 high-growth Irish life science, biotech, and medtech companies transforming the healthcare landscape. From Enterprise Ireland backed startups to global scale-ups, these are the emerging leaders of 2026.